Critical appraisal of inflammatory markers in cardiovascular risk stratification

Critical Reviews in Clinical Laboratory Sciences

Volumn 51, Issue 5, 2014, Pages 263-279

  Krintus, Magdalena ^a   Kozinski, Marek ^a   Kubica, Jacek ^a   Sypniewska, Grazyna ^a  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

Author keywords

Acute coronary syndrome; Coronary artery disease; CRP; Fibrinogen; GDF 15; Inflammation; Lp PLA2; MPO; Risk prediction

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; C REACTIVE PROTEIN; FIBRINOGEN; GROWTH DIFFERENTIATION FACTOR 15; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MYELOPEROXIDASE; TROPONIN; BIOLOGICAL MARKER;

CALIBRATION; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; CLINICAL TRIAL (TOPIC); CORONARY ARTERY DISEASE; ELECTROCARDIOGRAPHY; FIBROSIS; GENETIC ANALYSIS; HEART LEFT VENTRICLE OVERLOAD; HEART MUSCLE NECROSIS; HUMAN; HYPERTENSION; KIDNEY FUNCTION; LIPID ANALYSIS; NONHUMAN; ORGANIZATION; PATHOGENESIS; PATHOPHYSIOLOGY; PROGNOSIS; PROTEIN DETERMINATION; REVIEW; RISK ASSESSMENT; THORAX PAIN; CARDIOVASCULAR DISEASES; INFLAMMATION; METABOLISM;

BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; FIBRINOGEN; GROWTH DIFFERENTIATION FACTOR 15; HUMANS; INFLAMMATION;

EID: 84907440848     PISSN: 10408363     EISSN: 1549781X     Source Type: Journal    
DOI: 10.3109/10408363.2014.913549     Document Type: Review

References (127)

1. Go AS, Mozaffarian D, Roger VL, et al. Executive summary: heart disease and stroke statistics-2014 update: a report from the American Heart Association. Circulation 2014;129:399-410.
2. Yusuf S, Hawken S, Ounpuu S, et al.; INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364:937-52.
3. Hozawa A, Folsom AR, Sharrett AR, Chambless LE. Absolute and attributable risks of cardiovascular disease incidence in relation to optimal and borderline risk factors: comparison of African American with white subjects - Atherosclerosis Risk in Communities Study. Arch Intern Med 2007;167:573-9.
4. Khot UN, Khot MB, Bajzer CT, et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 2003; 290:898-904.
5. Ge Y, Wang TJ. Identifying novel biomarkers for cardiovascular disease risk prediction. J Intern Med 2012;272:430-9.
6. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-26.
7. Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol 2012;32:2045-51.
8. Kozinski M, Krzewina-Kowalska A, Kubica J, et al. Percutaneous coronary intervention triggers a systemic inflammatory response in patients treated for in-stent restenosis - comparison with stable and unstable angina. Inflamm Res 2005;54:187-93.
9. Kubica J, Kozinski M, Krzewina-Kowalska A, et al. Combined periprocedural evaluation of CRP and TNF-alpha enhances the prediction of clinical restenosis and major adverse cardiac events in patients undergoing percutaneous coronary interventions. Int J Mol Med 2005;16:173-80.
10. Paoletti R, Gotto Jr AM, Hajjar DP. Inflammation in atherosclerosis and implications for therapy. Circulation 2004;109:III20-6.
11. Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: testing and clinical relevance. Circulation 2007;115: 1285-95.
12. Linnet K1, Bossuyt PM, Moons KG, Reitsma JB. Quantifying the accuracy of a diagnostic test or marker. Clin Chem 2012;58: 1292-301.
13. Moons KG1, de Groot JA, Linnet K, et al. Quantifying the added value of a diagnostic test or marker. Clin Chem 2012;58:1408-17.
14. Folsom AR. Classical and novel biomarkers for cardiovascular risk prediction in the United States. J Epidemiol 2013;23:158-62.
15. Ge Y, Wang TJ. Circulating, imaging, and genetic biomarkers in cardiovascular risk prediction. Trends Cardiovasc Med 2011;21: 105-12.
16. Greenland P, Alpert JS, Beller GA, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2010;56:e50-103.
17. Myers GL, Christenson RH, Cushman M, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice guidelines: emerging biomarkers for primary prevention of cardiovascular disease. Clin Chem 2009;55:378-84.
18. Perk J, De Backer G, Gohlke H, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012;33: 1635-701.
19. Wilson PW, Pencina M, Jacques P, et al. C-reactive protein and reclassification of cardiovascular risk in the Framingham Heart Study. Circ Cardiovasc Qual Outcomes 2008;1:92-7.
20. Woodward M, Tunstall-Pedoe H, Rumley A, et al. Does fibrinogen add to prediction of cardiovascular disease? Results from the Scottish Heart Health Extended Cohort Study. Br J Haematol 2009;146:442-6.
21. Hatoum IJ, Cook NR, Nelson JJ, et al. Lipoprotein-associated phospholipase A2 activity improves risk discrimination of incident coronary heart disease among women. Am Heart J 2011;161: 516-22.
22. Daniels LB, Clopton P, Laughlin GA, et al. Growth-differentiation factor-15 is a robust, independent predictor of 11-year mortality risk in community-dwelling older adults: the Rancho Bernardo Study. Circulation 2011;123:2101-10.
23. Eggers KM, Kempf T, Wallentin L, et al. Change in growth differentiation factor 15 concentrations over time independently predicts mortality in community-dwelling elderly individuals. Clin Chem 2013;59:1091-8.
24. Rohatgi A, Patel P, Das SR, et al. Association of growth differentiation factor-15 with coronary atherosclerosis and mortality in a young, multiethnic population: observations from the Dallas Heart Study. Clin Chem 2012;58:172-82.
25. Inoue T, Kato T, Uchida T, et al. Local release of C-reactive protein from vulnerable plaque or coronary arterial wall injured by stenting. J Am Coll Cardiol 2005;46:239-45.
26. Ishikawa T, Hatakeyama K, Imamura T, et al. Involvement of C-reactive protein obtained by directional coronary atherectomy in plaque instability and developing restenosis in patients with stable or unstable angina pectoris. Am J Cardiol 2003;91: 287-92.
27. Tillett WS, Francis T. Serological reactions in pneumonia with a nonprotein somatic fraction of pneumococcus. J Exp Med 1930; 52:561-71.
28. Pankow JS, Folsom AR, Cushman M, et al. Familial and genetic determinants of systemic markers of inflammation: the NHLBI family heart study. Atherosclerosis 2001;154:681-9.
29. Koenig W. High-sensitivity C-reactive protein and atherosclerotic disease: from improved risk prediction to risk-guided therapy. Int J Cardiol 2013;168:5126-34.
30. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-9.
31. Lloyd-Jones DM, Liu K, Tian L, et al. Narrative review: assessment of C-reactive protein in risk prediction for cardiovascular disease. Ann Intern Med 2006;145:35-42.
32. Krintus M, Kozinski M, Stefanska A, et al. Value of C-reactive protein as a risk factor for acute coronary syndrome: a comparison with apolipoprotein concentrations and lipid profile. Mediators Inflamm 2012;2012:419804.
33. Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, Lowe G, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010;375:132-40.
34. Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, Pennells L, et al. C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med 2012;367: 1310-20.
35. Schiele F, Meneveau N, Seronde MF, et al. C-reactive protein improves risk prediction in patients with acute coronary syndromes. Eur Heart J 2010;31:290-7.
36. Tello-Montoliu A, Marín F, Roldán V, et al. A multimarker risk stratification approach to non-ST elevation acute coronary syndrome: implications of troponin T, CRP, NT pro-BNP and fibrin D-dimer levels. J Intern Med 2007;262:651-8.
37. Heeschen C, Hamm CW, Bruemmer J, et al. Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. CAPTURE Investigators. Chimeric c7E3 AntiPlatelet Therapy in Unstable angina REfractory to standard treatment trial. J Am Coll Cardiol 2000;35:1535-42.
38. Lindahl B, Toss H, Siegbahn A, et al. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during instability in coronary artery disease. N Engl J Med 2000; 343:1139-47.
39. Morrow DA, Rifai N, Antman EM, et al. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in myocardial infarction. J Am Coll Cardiol 1998;31:1460-5.
40. He LP, Tang XY, Ling WH, et al. Early C-reactive protein in the prediction of long-term outcomes after acute coronary syndromes: a meta-analysis of longitudinal studies. Heart 2010;96:339-46.
41. Swiatkiewicz I, Kozinski M, Magielski P, et al. Usefulness of C-reactive protein as a marker of early post-infarct left ventricular systolic dysfunction. Inflamm Res 2012;61:725-34.
42. Swiatkiewicz I, Kozinski M, Magielski P, et al. Value of C-reactive protein in predicting left ventricular remodelling in patients with a first ST-segment elevation myocardial infarction. Mediators Inflamm 2012;2012:250867.
43. Suleiman M, Khatib R, Agmon Y, et al. Early inflammation and risk of long-term development of heart failure and mortality in survivors of acute myocardial infarction predictive role of C-reactive protein. J Am Coll Cardiol 2006;47:962-8.
44. Biasucci LM, Koenig W, Mair J, et al. Study Group on Biomarkers in Cardiology of the Acute Cardiovascular Care Association of the European Society of Cardiology. How to use C-reactive protein in acute coronary care. Eur Heart J 2013;34:3687-90.
45. Hemingway H, Philipson P, Chen R, et al. Evaluating the quality of research into a single prognostic biomarker: a systematic review and meta-analysis of 83 studies of C-reactive protein in stable coronary artery disease. PLoS Med 2010;7:e1000286.
46. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207.
47. de Lorgeril M, Salen P, Abramson J, et al. Cholesterol lowering, cardiovascular diseases, and the rosuvastatin-JUPITER controversy. A critical reappraisal. Arch Intern Med 2010;170:1032-6.
48. Navarese EP, Buffon A, Andreotti F, et al. Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus. Am J Cardiol 2013;111:1123-30.
49. Ridker PM, MacFadyen JG, Fonseca FA, et al. Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER). Circ Cardiovasc Qual Outcomes 2009;2:616-23.
50. Choudhry NK, Patrick AR, Glynn RJ, et al. The cost-effectiveness of C-reactive protein testing and rosuvastatin treatment for patients with normal cholesterol levels. J Am Coll Cardioll 2011;57:784-91.
51. Ridker PM, Glynn RJ. The JUPITER trial: responding to the critics. Am J Cardiol 2010;106:1351-6.
52. Ridker PM, Thuren T, Zalewski A, et al. Interleukin-1b inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J 2011;162:597-605.
53. C Reactive Protein Coronary Heart Disease Genetics Collaboration (CCGC); Wensley F, Gao P, Burgess S, et al. Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data. BMJ 2011;342:548.
54. Elliott P, Chambers JC, Zhang W, et al. Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease. JAMA 2009;302:37-48.
55. Lowe GD. Fibrinogen assays for cardiovascular risk assessment. Clin Chem 2010;56:693-5.
56. Davalos D, Akassoglou K. Fibrinogen as a key regulator of inflammation in disease. Semin Immunopathol 2012;34:43-62.
57. Fibrinogen Studies Collaboration; Danesh J, Lewington S, Thompson SG, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 2005;294:1799-809.
58. Fibrinogen Studies Collaboration, Kaptoge S, White IR, Thompson SG, et al. Associations of plasma fibrinogen levels with established cardiovascular disease risk factors, inflammatory markers, and other characteristics: individual participant metaanalysis of 154,211 adults in 31 prospective studies: the fibrinogen studies collaboration. Am J Epidemiol 2007;166:867-79.
59. Emerging Risk Factors Collaboration, Danesh J, Erqou S, Walker M, et al. The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1. million participants in 104 prospective studies of cardiovascular diseases. Eur J Epidemiol 2007; 22: 839-69.
60. Ndrepepa G, Braun S, King L, et al. Relation of fibrinogen level with cardiovascular events in patients with coronary artery disease. Am J Cardiol 2013;111:804-10.
61. Sabater-Lleal M, Huang J, Chasman D, et al. Multiethnic metaanalysis of genome-wide association studies in4100 000 subjects identifies 23 fibrinogen-associated Loci but no strong evidence of a causal association between circulating fibrinogen and cardiovascular disease. Circulation 2013;128:1310-24.
62. Tousoulis D, Papageorgiou N, Androulakis E, et al. Lp-PLA2-a novel marker of atherosclerosis: to treat or not to treat? Int J Cardiol 2013;165:213-6.
63. Rosenson RS. Lp-PLA(2) and risk of atherosclerotic vascular disease. Lancet 2010;375:1498-500.
64. Cai A, Zheng D, Qiu R, et al. Lipoprotein-associated phospholipase A2 (Lp-PLA(2)): a novel and promising biomarker for cardiovascular risks assessment. Dis Markers 2013;34:323-31.
65. Tjoelker LW, Wilder C, Eberhardt C, et al. Anti-inflammatory properties of a platelet-activating factor acetylhydrolase. Nature 1995;374:549-53.
66. Packard CJ, O'Reilly DS, Caslake MJ, et al. Lipoproteinassociated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med 2000;343:1148-55.
67. Ballantyne CM, Hoogeveen RC, Bang H, et al. Lipoproteinassociated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Arch Intern Med 2005;165:2479-84.
68. Jenny NS, Solomon C, Cushman M, et al. Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) and risk of cardiovascular disease in older adults: results from the Cardiovascular Health Study. Atherosclerosis 2010;209:528-32.
69. Daniels LB, Laughlin GA, Sarno MJ, et al. Lipoprotein-associated phospholipase A2 is an independent predictor of incident coronary heart disease in an apparently healthy older population: the Rancho Bernardo Study. J Am Coll Cardiol 2008;51:913-9.
70. Sabatine MS, Morrow DA, O'Donoghue M, et al; PEACE Investigators. Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease. Arterioscler Thromb Vasc Biol 2007;27: 2463-9.
71. Cook NR, Paynter NP, Manson JE, et al. Clinical utility of lipoprotein-associated phospholipase A2 for cardiovascular disease prediction in a multiethnic cohort of women. Clin Chem 2012;58:1352-63.
72. Garza CA, Montori VM, McConnell JP, et al. Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: a systematic review. Mayo Clin Proc 2007;82:159-65.
73. Di Angelantonio E, Gao P, Pennells L, et al. Lipid-related markers and cardiovascular disease prediction. JAMA 2012;307: 2499-506.
74. Thompson A, Gao P, Orfei L, et al. Lp-PLA(2) Studies Collaboration. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 2010;375:1536-44.
75. Ridker PM, MacFadyen JG, Wolfert RL, et al. Relationship of lipoprotein-associated phospholipase A2 mass and activity with incident vascular events among primary prevention patients allocated to placebo or to statin therapy: an analysis from the JUPITER trial. Clin Chem 2012;58:877-86.
76. Stein EA. Lipopssteinsassociated phospholipase A2 measurements: mass, activity, but little productivity. Clin Chem 2012;58: 814-7.
77. Casas JP, Ninio E, Panayiotou A, et al. PLA2G7 genotype, lipoprotein-associated phospholipase A2 activity, and coronary heart disease risk in 10 494 cases and 15 624 controls of European Ancestry. Circulation 2010;121:2284-93.
78. Grallert H, Dupuis J, Bis JC, et al. Eight genetic loci associated with variation in lipoprotein-associated phospholipase A2 mass and activity and coronary heart disease: meta-analysis of genomewide association studies from five community-based studies. Eur Heart J 2012;33:238-51.
79. Heart Protection Study Collaborative Group. Lipoprotein-associated phospholipase A2 activity and mass in relation to vascular disease and nonvascular mortality. J Intern Med 2010;268: 348-58.
80. White HD, Simes J, Stewart RA, et al. Changes in lipoproteinassociated phospholipase A2 activity predict coronary events and partly account for the treatment effect of pravastatin: results from the long-term intervention with pravastatin in ischemic disease study. J Am Heart Assoc 2013;2:e000360.
81. Song JX, Ren JY, Chen H. Simvastatin reduces lipoproteinassociated phospholipase A2 in lipopolysaccharide-stimulated human monocyte-derived macrophages through inhibition of the mevalonate-geranylgeranyl pyrophosphate-RhoA-p38 mitogenactivated protein kinase pathway. J Cardiovasc Pharmacol 2011; 57:213-22.
82. Nicholls SJ, Kastelein JJ, Schwartz GG, et al. Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial. JAMA 2014;311: 252-62.
83. Tawakol A, Singh P, Rudd JH, et al. Effect of treatment for 12 weeks with rilapladib, a lipoprotein-associated phospholipase A2 inhibitor, on arterial inflammation as assessed with 18F-fluorodeoxyglucose-positron emission tomography imaging. J Am Coll Cardiol 2014;63:86-8.
84. White H, Held C, Stewart R, et al. Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease. Am Heart J 2010;160:655-61.
85. O'Donoghue ML, Braunwald E, White HD, et al. Study design and rationale for the stabilization of plaques using darapladibthrombolysis in myocardial infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome. Am Heart J 2011;162: 613-619.
86. The STABILITY Investigators. Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease. N Engl J Med 2014; in press. http://www.gsk.com/media/press-releases/2013/gsk-announces- top-line-results-from-pivotal-phase-iii-study-of-d.html (last accessed March 2014).
87. Callanan H, Jaffe AS, Saenger AK. Performance Evaluation of an Automated Assay for Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Activity. https://www.aacc.org/events/Annual-Meeting/abstracts/Documents/AACC-13-Abstracts-B316-B345. pdf (last accessed March 2014).
88. Jellinger PS, Smith DA, Mehta AE, et al. American Association of Clinical Endocrinologists' guidelines for management of dyslipidemia and prevention of atherosclerosis. Endocr Pract 2012; 181: 1-78.
89. Loria V, Dato I, Graziani F, et al. Myeloperoxidase: a new biomarker of inflammation in ischemic heart disease and acute coronary syndromes. Mediators Inflamm 2008;2008:135625.
90. Peacock WF, Nagurney J, Birkhahn R, et al. Myeloperoxidase in the diagnosis of acute coronary syndromes: the importance of spectrum. Am Heart J 2011;162:893-9.
91. Malle E, Marsche G, Panzenboeck U, et al. Myeloperoxidasemediated oxidation of high-density lipoproteins: fingerprints of newly recognized potential proatherogenic lipoproteins. Arch Biochem Biophys 2006;445:245-55.
92. Krintus M, Kuligowska M, Sypniewska G. The role of matrix metalloproteinase-3 in the development of atherosclerosis and cardiovascular events. eJIFCC 2006;17:1.
93. Sugiyama S, Okada Y, Sukhova GK, et al. Macrophage myeloperoxidase regulation by granulocyte macrophage colonystimulating factor in human atherosclerosis and implications in acute coronary syndromes. Am J Pathol 2001;158:879-91.
94. Tang WH, Wu Y, Nicholls SJ, et al. Plasma myeloperoxidase predicts incident cardiovascular risks in stable patients undergoing medical management for coronary artery disease. Clin Chem 2011;57:33-9.
95. Ferrante G, Nakano M, Prati F, et al. High levels of systemic myeloperoxidase are associated with coronary plaque erosion in patients with acute coronary syndromes: a clinicopathological study. Circulation 2010;122:2505-13.
96. Nicholls SJ, Tang WH, Brennan D, et al. Risk prediction with serial myeloperoxidase monitoring in patients with acute chest pain. Clin Chem 2011;57:1762-70.
97. Zhang R, Brennan ML, Fu X, et al. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA 2001;286:2136-42.
98. Meuwese MC, Stroes ES, Hazen SL, et al. Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol 2007;50:159-65.
99. Heslop CL1, Frohlich JJ, Hill JS. Myeloperoxidase and C-reactive protein have combined utility for long-term prediction of cardiovascular mortality after coronary angiography. J Am Coll Cardiol 2010;55:1102-9.
100. Wong ND, Gransar H, Narula J, et al. Myeloperoxidase, subclinical atherosclerosis, and cardiovascular disease events. JACC Cardiovasc Imaging 2009;2:1093-9.
101. Baldus S, Heeschen C, Meinertz T, et al; CAPTURE Investigators. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 2003;108:1440-5.
102. Apple FS, Smith SW, Pearce LA, et al. Assessment of the multiple-biomarker approach for diagnosis of myocardial infarction in patients presenting with symptoms suggestive of acute coronary syndrome. Clin Chem 2009;55:93-100.
103. Sypniewska G, Sawicki M, Krintus M, et al. The use of biochip cardiac array technology for early diagnosis of acute coronary syndromes. J Med Biochem 2009;28:293-9.
104. Apple FS, Smith SW, Pearce LA, et al. Myeloperoxidase improves risk stratification in patients with ischemia and normal cardiac troponin I concentrations. Clin Chem 2011;57:603-8.
105. Sawicki M, Sypniewska G, Kozinski M, et al. Diagnostic efficacy of myeloperoxidase for the detection of acute coronary syndromes. Eur J Clin Invest 2011;41:667-71.
106. Shih J, Datwyler SA, Hsu SC, et al. Effect of collection tube type and preanalytical handling on myeloperoxidase concentrations. Clin Chem 2008;54:1076-9.
107. Searle J, Shih J, Muller R, et al. The role of myeloperoxidase (MPO) for prognostic evaluation in sensitive cardiac troponin I negative chest pain patients in the emergency department. Eur Heart J Acute Cardiovasc Care 2013;2:203-10.
108. Scirica BM, Sabatine MS, Jarolim P, et al. Assessment of multiple cardiac biomarkers in non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 trial. Eur Heart J 2011;32:697-705.
109. Khan DA, Sharif MS, Khan FA. Diagnostic performance of highsensitivity troponin T, myeloperoxidase, and pregnancy-associated plasma protein A assays for triage of patients with acute myocardial infarction. Korean J Lab Med 2011;31:172-8.
110. Unsicker K, Spittau B, Krieglstein K, et al. The multiple facets of the TGF-b family cytokine growth/differentiation factor-15/macrophage inhibitory cytokine-1. Cytokine Growth Factor Rev 2013;24:373-84.
111. Bonaterra GA, Zugel S, Thogersen J, et al. Growth differentiation factor 15 deficiency inhibits atherosclerosis progression by regulating IL-6-dependent inflammatory response to vascular injury. J Am Heart Assoc 2012;1:e002550.
112. Breit SN, Carrero JJ, Wang-Wei Tsai V, et al. Macrophage inhibitory cytokine-1 (MIC-1/GDF15) and mortality in end-stage renal disease. Nephrol Dial Transplant 2012;27:70-5.
113. Kempf T, Wollert KC. Growth differentiation factor-15 in heart failure. Heart Fail Clin 2009;5:537-47.
114. Bermudez B, Lopez S, Pacheco YM, et al. Influence of postprandial triglyceride-rich lipoproteins on lipid mediated gene expression in smooth muscle cells of the human coronary artery. Cardiovasc Res 2008;79:294-303.
115. Kempf T, Zarbock A, Widera C, et al. GDF-15 is an inhibitor of leukocyte integrin activation required for survival after myocardial infarction in mice. Nat Med 2011;7:581-8.
116. Johnen H, Kuffner T, Brown DA, et al. Increased expression of the TGF-b superfamily cytokine MIC-1/GDF15 protects ApoE(-/-) mice from the development of atherosclerosis. Cardiovasc Pathol 2012;21:499-505.
117. Eggers KM, Lind L, Sundström J, et al. Relations of growthdifferentiation factor-15 to biomarkers reflecting vascular pathologies in a population-based sample of elderly subjects. Scand J Clin Lab Invest 2012;72:45-51.
118. Ho JE, Mahajan A, Chen MH, et al. Clinical and genetic correlates of growth differentiation factor-15 in the community. Clin Chem 2012; 58:1582-91.
119. Wiklund FE, Bennet AM, Magnusson PKE, et al. Macrophage inhibitory cytokine-1 (MIC-1/GDF15): a new marker of all-cause mortality. Aging Cell 2010;9:1057-64.
120. Schnabel RB, Schulz A, Messow CM, et al. Multiple marker approach to risk stratification in patients with stable coronary artery disease. Eur Heart J 2010;31:3024-31.
121. Eggers KM, Kempf T, Lagerqvist B, et al. Growth-differentiation factor-15 for long-term risk prediction in patients stabilized after an episode of non-ST-segment-elevation acute coronary syndrome. Circ Cardiovasc Genet 2010;3:88-96.
122. Meune C, Balmelli C, Twerenbold R, et al. Utility of 14 novel biomarkers in patients with acute chest pain and undetectable levels of conventional cardiac troponin. Int J Cardiol 2013;167: 1164-9.
123. Widera C, Pencina MJ, Bobadilla M, et al. Incremental prognostic value of biomarkers beyond the GRACE score and high-sensitivity cardiac troponin T in non-ST-elevation acute coronary syndrome. Clin Chem 2013;59:1497-1505.
124. Lindahl B. The story of growth differentiation factor-15: another piece of the puzzle. Clin Chem 2013;59:1550-1552.
125. Wollert KC, Kempf T, Peter T, et al. Prognostic value of growthdifferentiation factor-15 in patients with non-ST-elevation acute coronary syndrome. Circulation 2007;115:962-71.
126. Frankenstein L1, Remppis A, Frankenstein J, et al. Reference change values and determinants of variability of NT-proANP and GDF15 in stable chronic heart failure. Basic Res Cardiol 2009; 104:731-8.
127. Rohatgi A, de Lemos JA. The report card on growth differentiation factor 15: consistent marks but not yet ready for promotion. Circ Cardiovasc Genet 2009;2:209-11.